Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 4/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | VEGFA | P15692 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4723467 | 0.87 | L3MBTL1 (0.42) | L3MBTL1ACVR1BRD4RAPGEF4HTR6 | |
| SCHEMBL5124659 | 0.87 | L3MBTL1 (0.45) | L3MBTL1ACVR1BRD4RAPGEF4POLB | |
| SCHEMBL5117141 | 0.84 | L3MBTL1 (0.43) | L3MBTL1ACVR1BRD4RAPGEF4POLB | |
| SCHEMBL5116653 | 0.82 | L3MBTL1 (0.45) | L3MBTL1ACVR1BRD4RAPGEF4POLB | |
| SCHEMBL5113381 | 0.80 | L3MBTL1 (0.45) | L3MBTL1ACVR1BRD4RAPGEF4POLB | |
| SCHEMBL5124281 | 0.79 | L3MBTL1 (0.42) | L3MBTL1ACVR1BRD4RAPGEF4POLB | |
| SCHEMBL4777744 | 0.79 | LRRK2 (0.44) | MAPTMEN1KMT2ACA1CA2 | |
| SCHEMBL4843165 | 0.78 | LRRK2 (0.54) | — | |
| SCHEMBL5114610 | 0.77 | PTK2 (0.46) | CDK1 | |
| SCHEMBL5113429 | 0.77 | PTK2 (0.46) | CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004295-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-03 | — | — | US | disclosed |
| US-20080004295-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-03 | — | — | US | disclosed |
| US-20080004295-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004295-A1 | NOVEL COMPOUNDS | SYK, BTK, LCK | L3MBTL1 3847/4885ACVR1 4241/4885BRD4 1433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.